NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyEarly to Definitive Clinical Trials (R61/R33 Clinical Trial Required)
About This Grant
The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose early to definitive clinical trials. Trials testing drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical or non-pharmacological interventions are of interest to this initiative. The trials should align with the research mission of the participating Institutes, Centers, and Offices (ICOs) of the NIH. The NOFO will utilize the R61/R33 activity code, a bi-phasic, milestone-driven award. The R61 phase provides support for planning activities, and the R33 phase provides support for a clinical trial, with a maximum project period of 7 years. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and relevant projects. Investigators with expertise in clinical trial planning, design, implementation, intervention development, and/or stakeholder engagement are encouraged to consider applying for the NOFO.
Grant Summary
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) is a National Institutes of Health grant providing funding that varies by award for municipality, school district, university. This is a forecast: it is not yet open for applications, and the estimated deadline is 2027-07-31. Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 800+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Not stated by funder
Estimated 2027-07-31
- 1Confirm your organization is eligible for Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required): Frequently Asked Questions
Who is eligible for the Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)?
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) is offered by National Institutes of Health. The listing names these applicant types: municipality, school district, university, tribal government, nonprofit, small business. It is open to organizations nationwide unless the funder specifies otherwise. The funder's eligibility section is the authority, so confirm your organization type, location, and the population or project served against it before applying.
How much funding does the Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) provide?
National Institutes of Health does not publish a set award amount for Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required), so award sizes vary. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs, and confirm the expected range with the funder.
When is the Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) deadline?
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) is a forecast from National Institutes of Health: it is not yet open for applications. The funder's estimated deadline is 2027-07-31, and forecast dates often change. Confirm the official posting with the funder before you prepare an application.
How do you apply for the Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)?
To apply for Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.
Browse More Grants
Related Grants
State Veterans Home Construction Grant Program
Construction of State Home Facilities — up to $275M
Advancing Global Health
Bureau of Global Health Security and Diplomacy — up to $250M
Title X Family Planning Services Grants
Office of the Assistant Secretary for Health — up to $22M
Fiscal Year (FY) 2027 Service Area Competition (SAC)
Health Resources and Services Administration — up to $10.1M
Occupational Safety and Health Education and Research Centers (T42)
Centers for Disease Control and Prevention - ERA — up to $9M
BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)
National Institutes of Health — up to $8M